{"id":"W2278057905","doi":"10.1200/jco.2004.22.90140.7022","title":"A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1<sup>st</sup> line or 2<sup>nd</sup> line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial","year":2004,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Lung cancer; Rash; Clinical endpoint; Erlotinib Hydrochloride; Regimen; Chemotherapy; Pemetrexed; Oncology; Carboplatin; Chemotherapy regimen; Placebo; Randomized controlled trial; Gastroenterology; Epidermal growth factor receptor; Cancer; Cisplatin; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0132631,0.0004732748,0.00976462,0.000379815,0.0000642122,0.000009384715,0.0003335501,0.0006701146,0.0002064059],"category_scores_gemma":[0.01694616,0.0002830464,0.002164645,0.0005172906,0.0003576884,0.0002338384,0.00004365159,0.001168118,2.871489e-7],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001116473,"about_ca_system_score_gemma":0.04144474,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01042467,"about_ca_topic_score_gemma":0.04478125,"domain_scores_codex":[0.9844123,0.001898578,0.01131332,0.0005031102,0.001395514,0.0004772423],"domain_scores_gemma":[0.9779771,0.01037809,0.009172579,0.0003022794,0.001690163,0.0004797676],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9418529,0.009386052,0.005478578,0.000153381,0.005914295,0.00009509577,0.0005438735,0.02916705,0.00001501774,0.00001508448,0.0003953869,0.006983289],"study_design_scores_gemma":[0.9635171,0.02542936,0.001354291,0.00122323,0.004983472,0.000005418561,0.0001410638,0.001668817,0.00004635628,0.00004652378,0.001354061,0.0002303009],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9838412,0.0006228908,0.0003822101,0.003023786,0.002516264,0.009243582,0.0001575647,0.000008217088,0.0002042992],"genre_scores_gemma":[0.9891787,0.0007391328,0.005961256,0.0008584893,0.002391348,0.0005240501,0.00004872945,0.00005745684,0.000240867],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04032827,"threshold_uncertainty_score":0.9999622,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0520902160985434,"score_gpt":0.4512543726723138,"score_spread":0.3991641565737704,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}